Decoupling Treatment from Hallucinations: New Pathways in Psychedelic Drug Research

**Psychedelic research** has taken a significant step forward with new findings indicating that **therapeutic benefits** can be separated from **hallucinogenic effects**. The study, published in Science, reveals that these effects operate through distinct neural circuits, demonstrated through experiments with mouse models. **Anti-anxiety effects** were examined using behavioral tests such as the elevated plus maze and marble burying test. Mice dosed with the psychedelic compound **2,5-dimethoxy-4-iodoamphetamine (DOI)** displayed reduced anxiety without hallucinogenic behavior after some time. These effects were traced to specific neurons in the **medial prefrontal cortex** using the molecular tagging tool **scFLARE2**. By tagging and reactivating these neurons, researchers could replicate the anti-anxiety benefits, offering insights into targeted treatment approaches. The study utilized **optogenetics** to selectively activate DOI-responsive neurons, revealing distinct neuron types and their roles in the broader psychedelic-responsive network. Interestingly, not all neurons depended on the 5-HT2AR receptor, suggesting their activation resonates beyond initial receptor engagement. The study holds potential for developing **safer psychedelic therapies**, informed by a deeper understanding of the neural circuitry involved. Funding for the research came from multiple prestigious sources, underscoring its significance in advancing psychiatric treatments.